Sarepta Therapeutics Inc (SRPT) to Post FY2017 Earnings of ($3.04) Per Share, William Blair Forecasts

Sarepta Therapeutics Inc (NASDAQ:SRPT) – Equities research analysts at William Blair decreased their FY2017 earnings estimates for shares of Sarepta Therapeutics in a research note issued on Monday. William Blair analyst T. Lugo now forecasts that the biotechnology company will post earnings per share of ($3.04) for the year, down from their prior forecast of ($3.03). William Blair has a “Outperform” rating on the stock. William Blair also issued estimates for Sarepta Therapeutics’ Q4 2017 earnings at ($0.34) EPS, Q1 2018 earnings at ($0.38) EPS, Q2 2018 earnings at ($0.54) EPS, Q3 2018 earnings at ($0.28) EPS, Q4 2018 earnings at ($0.15) EPS and FY2018 earnings at ($1.35) EPS.

SRPT has been the subject of several other reports. Robert W. Baird reiterated a “buy” rating and issued a $101.00 target price on shares of Sarepta Therapeutics in a research note on Tuesday, October 17th. Oppenheimer reiterated a “buy” rating and issued a $76.00 target price on shares of Sarepta Therapeutics in a research note on Wednesday, December 27th. Royal Bank of Canada assumed coverage on shares of Sarepta Therapeutics in a research note on Monday, January 22nd. They issued an “outperform” rating for the company. BidaskClub upgraded shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, January 13th. Finally, Leerink Swann reiterated an “outperform” rating and issued a $77.00 target price on shares of Sarepta Therapeutics in a research note on Friday, January 19th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and eighteen have given a buy rating to the company. Sarepta Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $64.65.

Shares of Sarepta Therapeutics (NASDAQ SRPT) opened at $62.29 on Wednesday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 9.52 and a current ratio of 10.44. Sarepta Therapeutics has a 12 month low of $26.26 and a 12 month high of $68.90. The company has a market cap of $4,030.00, a P/E ratio of -30.53 and a beta of 1.49.

In related news, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of the business’s stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $55.89, for a total value of $372,618.63. Following the completion of the sale, the director now owns 13,333 shares of the company’s stock, valued at approximately $745,181.37. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 9.60% of the stock is currently owned by insiders.

Several institutional investors have recently added to or reduced their stakes in the company. Ameritas Investment Partners Inc. grew its holdings in shares of Sarepta Therapeutics by 6.3% in the second quarter. Ameritas Investment Partners Inc. now owns 4,561 shares of the biotechnology company’s stock valued at $154,000 after purchasing an additional 271 shares during the period. Advisor Group Inc. grew its holdings in shares of Sarepta Therapeutics by 3.2% in the second quarter. Advisor Group Inc. now owns 10,402 shares of the biotechnology company’s stock valued at $351,000 after purchasing an additional 326 shares during the period. Parametric Portfolio Associates LLC grew its holdings in shares of Sarepta Therapeutics by 0.8% in the second quarter. Parametric Portfolio Associates LLC now owns 109,852 shares of the biotechnology company’s stock valued at $3,703,000 after purchasing an additional 818 shares during the period. C WorldWide Group Holding A S grew its holdings in shares of Sarepta Therapeutics by 0.8% in the third quarter. C WorldWide Group Holding A S now owns 122,469 shares of the biotechnology company’s stock valued at $5,555,000 after purchasing an additional 941 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Sarepta Therapeutics by 39.5% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,448 shares of the biotechnology company’s stock valued at $192,000 after purchasing an additional 977 shares during the period. 81.97% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Sarepta Therapeutics Inc (SRPT) to Post FY2017 Earnings of ($3.04) Per Share, William Blair Forecasts” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/02/07/sarepta-therapeutics-inc-srpt-to-post-fy2017-earnings-of-3-04-per-share-william-blair-forecasts.html.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Earnings History and Estimates for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply